Biofermin Pharmaceutical Co Ltd (4517)

Tokyo

Currency in JPY

3,130.0

0.0(0.00%)

Closed·27/07

Day's Range

3,110.0

3,215.0

52 wk Range

3,110.0

3,215.0

4517 Income Statement

Featured here, the Income Statement (earnings report) for Biofermin Pharmaceutical Co Ltd, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Period Ending:

2012

31/03

2013

31/03

2014

31/03

2015

31/03

2016

31/03

2017

31/03

2018

31/03

2019

31/03

2020

31/03

2021

31/03

Total Revenues

aa.aa

10,618

10,877

11,542

11,924

10,811

Total Revenues Growth

aa.aa

+9.85%

+2.44%

+6.11%

+3.31%

-9.33%

Cost Of Revenues

aa.aa

4,033

3,769

4,545

4,601

4,497

Gross Profit

aa.aa

6,585

7,108

6,997

7,323

6,314

Gross Profit Growth

aa.aa

+13.2%

+7.94%

-1.56%

+4.66%

-13.78%

Gross Profit Margin %

aa.aa

62.02%

65.35%

60.62%

61.41%

58.4%

Other Operating Expenses, Total

aa.aa

3,887

3,915

3,821

4,258

4,255

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+9.83%	+0.72%	-2.4%	+11.44%	-0.07%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	269	260	342	467	436
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	3,489	3,439	3,270	3,680	3,675
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	94	176	161	71	107

Operating Income

aa.aa

2,698

3,193

3,176

3,065

2,059

Operating Income Growth

aa.aa

+18.44%

+18.35%

-0.53%

-3.49%

-32.82%

EBIT Margin %

aa.aa

25.41%

29.36%

27.52%

25.7%

19.05%

Net Interest Expenses

aa.aa

Net Interest Expenses Growth

aa.aa

-4.29%

+5.97%

+1.41%

+2.78%

Interest Expense, Total

aa.aa

Interest And Investment Income

aa.aa

Other Non Operating Expenses, Total

aa.aa

-5

-7

EBT, Excl. Unusual Items

aa.aa

2,760

3,257

3,301

3,144

2,137

Gain (Loss) On Sale Of Assets

aa.aa

-51

-150

-16

-6

-17

Other Unusual Items, Total

aa.aa

-12

EBT, Incl. Unusual Items

aa.aa

2,709

3,107

3,273

3,138

2,120

EBT, Incl. Unusual Items Growth

aa.aa

+17.89%

+14.69%

+5.34%

-4.12%

-32.44%

EBT, Incl. Unusual Items Margin

aa.aa

25.51%

28.56%

28.36%

26.32%

19.61%

Income Tax Expense

aa.aa

810

897

968

898

572

Net Income to Company

aa.aa

1,899

2,210

2,305

2,240

1,548

Minority Interest

aa.aa

Net Income

aa.aa

1,899

2,210

2,305

2,240

1,548

Net Income Growth

aa.aa

+19.51%

+16.38%

+4.3%

-2.82%

-30.89%

Net Income Margin %

aa.aa

17.88%

20.32%

19.97%

18.79%

14.32%

Preferred Dividend and Other Adjustments

aa.aa

Net Income to Common Excl. Extra Items

aa.aa

1,899

2,210

2,305

2,240

1,548

Basic EPS - Continuing Operations

aa.aa

159.02

184.97

192.76

187.28

129.42

Basic EPS - Continuing Operations Growth

aa.aa

+19.51%

+16.32%

+4.21%

-2.84%

-30.89%

Diluted EPS - Continuing Operations

aa.aa

158.82

184.75

192.58

187.08

129.2

Diluted EPS - Continuing Operations Growth

aa.aa

+19.39%

+16.33%

+4.24%

-2.86%

-30.94%

Basic Weighted Average Shares Outstanding

aa.aa

11.94

11.95

11.96

Diluted Weighted Average Shares Outstanding

aa.aa

11.96

11.97

11.98

Dividend Per Share

aa.aa

Dividend Per Share Growth

aa.aa

EBITDA

aa.aa

3,791

4,120

4,116

4,134

3,110

EBITDA Growth

aa.aa

+7.39%

+8.68%

-0.1%

+0.44%

-24.77%

EBITDA Margin %

aa.aa

35.7%

37.88%

35.66%

34.67%

28.77%

EBIT

aa.aa

2,698

3,193

3,176

3,065

2,059

* In Millions of JPY (except for per share items)

NSE 30

5,162.64

-3.61

-0.07%

NSE All Share

141,618.20

-143.16

-0.10%

US 30

45,439.50

+21.4

+0.05%

US 500

6,470.60

+4.7

+0.07%

FTSE 100

9,265.75

-0.05

0.00%

DAX

24,143.99

-35.88

-0.15%

South Africa Top 40

94,085.33

-661.75

-0.70%

Market Movers

Name	Last	Chg. %	Vol.
Fcmb	11.000	-1.79%	102.95M
Nigerian Breweries	70.50	+0.71%	7.19M
Nahco	105.950	+1.88%	5.16M
Zenith Bank	70.00	-0.85%	3.29M
Guaranty Trust Holding	97.40	-0.61%	2.51M
BUA Foods	545.00	-7.63%	1.31M
Nestle Nigeria	1,871.00	-1.01%	307.92K

Name	Last	Chg. %	Vol.
Skye Shelter Fund	331.70	+10.00%	37.98K
Airtel Africa	2,541.50	+10.00%	103.00
Austin Laz	2.95	+8.46%	36.76K
Union Dicon Salt	12.25	+9.38%	41.98K
Cutix	3.880	+9.30%	2.59M
University Pre	6.000	+8.30%	23.32K
McNichols	3.83	+7.89%	199.05K

Name	Last	Chg. %	Vol.
Geregu Power	1,027.40	-10.00%	1.66K
Tripple Gee and Co	5.04	-10.00%	13.60K
Okomu Oil Palm	918.00	-10.00%	62.80K
Transcorp Power	257.90	-9.98%	132.26K
Thomaswy	3.00	0.00%	46.45K
Presco	1,350.00	-8.78%	102.17K
Chellarams	9.60	-8.57%	41.84K

Trending Stocks

Name	Last	Chg. %	Vol.
Ellah Lakes	15.20	-0.65%	4.07M
Guaranty Trust Holding	97.40	-0.61%	2.36M
MTN Nigeria	413.00	-5.06%	419.06K
UBA	48.75	+0.72%	2.16M
Cutix	3.880	+9.30%	2.59M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaaaaaaaa	5,399.90	+45.20%	7,840.65
Aa Aa A	516.00	+36.56%	704.65
Aaaaaaaaaaaaa	144.90	+33.37%	193.25
Aaaaaaaaaaaaaaa Aa	1,871.00	+30.71%	2,445.58
A Aaaaaaa	600.00	+22.16%	732.96
Aaaaaaa Aaaa A	69.20	+18.47%	81.98

Name	Last	Upside	Fair Value
Aaaaaaaaaa	5,399.90	+45.20%	7,840.65
Aa Aa A	516.00	+36.56%	704.65
Aaaaaaaaaaaaa	144.90	+33.37%	193.25
Aaaaaaaaaaaaaaa Aa	1,871.00	+30.71%	2,445.58
A Aaaaaaa	600.00	+22.16%	732.96
Aaaaaaa Aaaa A	69.20	+18.47%	81.98

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers

Popular Searches

Please try another search

Biofermin Pharmaceutical Co Ltd (4517)

4517 Income Statement

Trending Stocks